Pancreatic Adenocarcinoma & Staging
- Pancreatic ductal adenocarcinoma is a sneaky, ill-defined mass that often announces itself not by being bright, but by being darker than the rest of the gland on a contrast scan.
- It loves the pancreatic head, where it kinks the bile duct and pancreatic duct and gives you the classic "double duct sign."
- Staging is mostly about geography: where does the tumor sit relative to the big arteries and veins right next to the pancreas?
- That artery-and-vein relationship sorts patients into resectable, borderline resectable, or locally advanced — which decides whether a surgeon, a chemo regimen, or both go first.
- The right test is a dedicated dual-phase pancreas-protocol CT, ideally read before any biopsy or stent muddies the picture.
Pancreatic ductal adenocarcinoma (usually just called pancreatic cancer, or PDAC) has a reputation, and sadly it earned it. It's one of the few tumors where the radiologist's main job isn't really "is there cancer?" so much as "can a surgeon actually get this out?" Because for this tumor, surgery is the only real shot at cure, and whether surgery is possible comes down to a few millimeters of fat around some very important plumbing.
So this page is less a monster-of-the-week and more a real-estate appraisal. Let's go look at the property.
What it looks like (or rather, doesn't)
Most masses you hunt for by looking for something that lights up. PDAC is the opposite kind of villain: it's a dense, scarry, fibrous tumor with relatively few blood vessels, so when you give IV contrast, it under-enhances. The normal pancreas around it blushes nicely; the tumor stays sullen and gray. You're looking for a hypoenhancing (darker-than-its-neighbor) region, often with frustratingly fuzzy edges.
Think of pouring dye into a sponge. The healthy spongy pancreas soaks it up and brightens. The tumor is more like a hardened patch of dried glue in that sponge — the dye can't get in, so it stays dull. That contrast difference is frequently the only way you see the thing.
Because the tumor is so low-contrast against the gland, timing matters enormously. A dedicated pancreas-protocol CT grabs two phases: a pancreatic (late arterial) phase, when the normal gland is at peak blush and the tumor stands out darkest, and a portal venous phase to assess the veins and look for liver spread. A routine single-phase scan can quietly miss a small tumor.
The secondary signs that give it away
When the mass itself is subtle, the consequences shout. PDAC in the pancreatic head sits right where the bile duct and the pancreatic duct funnel toward the bowel, so a tumor there squeezes both shut. Upstream, both ducts balloon — the double duct sign, two dilated tubes ending abruptly at the same spot. It's the imaging equivalent of two roads both dead-ending at the same landslide.
Other tells: abrupt cutoff of the pancreatic duct, atrophy of the gland upstream of the blockage (the dammed-off part withers), and sometimes a subtly enlarged contour. Don't confuse this with the duct dilation and calcifications of chronic pancreatitis — the two can coexist and mimic each other, which is one of the genuine headaches of this region.
A pancreatic head mass is not automatically adenocarcinoma. A cystic, lobulated, or duct-communicating lesion may be an IPMN or other cystic neoplasm — see pancreatic cystic lesions. And a focal mass-like swelling can be autoimmune or focal chronic pancreatitis. The enhancement pattern, the duct behavior, and the company it keeps all matter.
Staging is all about the neighbors
Here's the part that actually changes someone's life. The pancreas is wrapped around two critical arteries — the celiac axis and the superior mesenteric artery (SMA) — and drapes over two critical veins — the superior mesenteric vein (SMV) and the portal vein. Whether the tumor can be removed depends almost entirely on how much it's leaning on these vessels.
The mental model surgeons and radiologists share is degree of contact: how much of the vessel's circumference is touched, and whether the vessel wall looks deformed or narrowed.
| Category | Rough vessel relationship | What it means |
|---|---|---|
| Resectable | Clear fat plane around the major arteries and veins; little or no contact | Surgeon can likely take it out cleanly |
| Borderline resectable | Limited contact with arteries, or contact/short narrowing of the SMV–portal vein that's reconstructable | Often chemo first, then re-image and consider surgery |
| Locally advanced (unresectable) | Tumor encases an artery, or the vein is occluded over a long segment without a reconstruction option | Not surgically curable; systemic treatment leads |
Note the asymmetry: arteries (celiac, SMA, and the hepatic artery) are the unforgiving ones — even modest tumor wrapping around an artery is a big deal. Veins are a little more forgiving, because a short involved segment of SMV or portal vein can sometimes be cut out and rebuilt.
The single most useful sentence you can put in a report: how much of each major vessel's circumference the tumor touches, and whether that vessel is deformed or narrowed. That one observation, more than the tumor's size, decides the treatment path.
Don't forget to look away from the pancreas
Local geography decides resectability, but distant spread overrules everything. Before anyone schedules an operation, you scan for metastatic disease — most often liver lesions and peritoneal deposits, sometimes distant nodes. A whisper of ascites or a tiny low-density liver lesion can flip the whole plan. The liver is best judged on that portal venous phase, which is exactly why the pancreas protocol grabs it.
Image before you stent. If an obstructed bile duct gets a metal stent first, the surrounding inflammation and the streaky stent artifact can blur the very tumor-vessel interface staging depends on. When you can, get the staging pancreas-protocol CT up front.
The one thing to remember
For pancreatic adenocarcinoma, the radiologist's verdict isn't really about the mass — it's about the fat planes around the celiac axis, the SMA, the SMV, and the portal vein, plus a careful sweep for distant disease. Describe those relationships precisely, and you've answered the only question the whole team is actually asking: can we still operate?